2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor
- PMID: 6097265
2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor
Abstract
2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl] - (1S,3S,5S) -2-azabicyclo [3.3.0] octane-3-carboxylic acid (Hoe 498) is a new, very effective and long lasting, nonsulfhydryl angiotensin I converting enzyme inhibitor. Using hip-his-leu as substrate, the IC50-values for Hoe 498 and its diacid derivative were 26 or 4.2 nmol/l, respectively. Hoe 498 acts as a prodrug. It is hydrolyzed by an esterase into its active diacid derivative. Sera contain high esterase activities. In comparison to sera from man, dog and rabbit, rat sera have the highest esterase activity. Hoe 498 or its diacid derivative do not modulate the membrane bound adenylatecyclase system of tissues under investigation. The results are discussed in respect of the regulation of the angiotensin II-synthesis and to the regulation of Ca2+-channels in membranes.
Similar articles
-
Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.Arzneimittelforschung. 1984;34(10B):1406-10. Arzneimittelforschung. 1984. PMID: 6097266
-
Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).Arzneimittelforschung. 1984;34(10B):1411-6. Arzneimittelforschung. 1984. PMID: 6097267
-
2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.Arzneimittelforschung. 1984;34(10B):1426-30. Arzneimittelforschung. 1984. PMID: 6097269
-
The present molecules of converting enzyme inhibitors.J Cardiovasc Pharmacol. 1985;7 Suppl 1:S2-11. doi: 10.1097/00005344-198507001-00002. J Cardiovasc Pharmacol. 1985. PMID: 2580170 Review.
-
Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications.Clin Physiol Biochem. 1990;8 Suppl 1:44-52. Clin Physiol Biochem. 1990. PMID: 2147879 Review.
Cited by
-
Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.Drugs. 1990 Jan;39(1):110-35. doi: 10.2165/00003495-199039010-00009. Drugs. 1990. PMID: 2138076 Review.
-
Clinical pharmacokinetics of the newer ACE inhibitors. A review.Clin Pharmacokinet. 1990 Sep;19(3):177-96. doi: 10.2165/00003088-199019030-00003. Clin Pharmacokinet. 1990. PMID: 2203579 Review.
-
Lack of interaction between ramipril and simvastatin.Eur J Clin Pharmacol. 1994;47(4):373-5. doi: 10.1007/BF00191171. Eur J Clin Pharmacol. 1994. PMID: 7875191 Clinical Trial.
-
Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.Eur J Clin Pharmacol. 1993;45(3):241-6. doi: 10.1007/BF00315390. Eur J Clin Pharmacol. 1993. PMID: 8276048 Clinical Trial.
-
Preclinical studies on angiotensin converting enzyme inhibitors.Cardiovasc Drugs Ther. 1987;1(1):15-27. doi: 10.1007/BF02125829. Cardiovasc Drugs Ther. 1987. PMID: 3154307 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Miscellaneous